Viewing data from:

PRIMSOL

NDA

TRIMETHOPRIM HYDROCHLORIDE | N074374 | PANGEA PHARMACEUTICALS LLC

1 strength0 unique patents0 unique exclusivities

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

4 trials from ClinicalTrials.gov — 4 recruiting

Trial	Phase	Status	Sponsor	Enrollment	Dates
Self-Start Triage Model for Post-Botox® Lower Urinary Tract Symptoms NCT07648290	Early Phase 1	Not Yet Recruiting	The Cleveland Clinic	260	2026-07-01 → 2028-03-31
Study on the Impact of Decolonization Treatment of Pneumocystis Jirovecii on the Frequency of Acute Exacerbation in COPD NCT07665359	N/A	Not Yet Recruiting	Second Affiliated Hospital, School of Medicine, Zhejiang University	630	2026-07-01 → 2029-05-01
A Clinical Trial of Extended (High) Treatment Dose Antibiotics in Combination With Methenamine Hippurate Compared to the Standard of Care (Either Prophylactic (Low) Dose Antibiotic Treatment or Methenamine Hippurate) in Females With Chronic Urinary Tract Infection NCT07202949	Phase 2	Recruiting	University College, London	192	2026-02-26 → 2027-11
Effects of Treatments on Atopic Dermatitis NCT01631617	Phase 2	Recruiting	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	130	2012-09-18 → 2027-01-01

Source: ClinicalTrials.gov. Trials matched by ingredient name.

Products (1)

#001 — EQ 25MG BASE/5ML

0 patents0 exclusivities▴

SOLUTION;ORAL | Approved: Jun 23, 1995

No patent or exclusivity listings for this strength.